Humoral Responses Elicited After a Fifth Dose of SARS-CoV-2 MRNA Bivalent Vaccine

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2023 Sep 28

PMID 37766332

Authors

Alexandra Tauzin

Guillaume Beaudoin-Bussieres

Mehdi Benlarbi

Manon Nayrac

Yuxia Bo

Gabrielle Gendron-Lepage

Halima Medjahed

Josee Perreault

Laurie Gokool

Pascale Arlotto

Chantal Morrisseau

Cecile Tremblay

Daniel E Kaufmann

Valerie Martel-Laferriere

Ines Levade

Marceline Cote

Renee Bazin

Andres Finzi

Affiliations

Soon will be listed here.

Abstract

While an important part of the world's population is vaccinated against SARS-CoV-2, new variants continue to emerge. We observe that even after a fifth dose of the mRNA bivalent vaccine, most vaccinated individuals have antibodies that poorly neutralize several Omicron subvariants, including BQ.1.1, XBB, XBB.1.5, FD.1.1, and CH.1.1. However, Fc-effector functions remain strong and stable over time against new variants, which may partially explain why vaccines continue to be effective. We also observe that donors who have been recently infected have stronger antibody functional activities, including neutralization and Fc-effector functions, supporting the observations that hybrid immunity leads to better humoral responses.

Citing Articles

Temperature-dependent Spike-ACE2 interaction of Omicron subvariants is associated with viral transmission.

Benlarbi M, Ding S, Belanger E, Tauzin A, Poujol R, Medjahed H mBio. 2024; 15(8):e0090724.

PMID: 38953636 PMC: 11323525. DOI: 10.1128/mbio.00907-24.

Differentiating Cell Entry Potentials of SARS-CoV-2 Omicron Subvariants on Human Lung Epithelium Cells.

Katte R, Ao Y, Xu W, Han Y, Zhong G, Ghimire D Viruses. 2024; 16(3).

PMID: 38543757 PMC: 10975267. DOI: 10.3390/v16030391.

References

Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E . Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022; 386(16):1532-1546. PMC: 8908811. DOI: 10.1056/NEJMoa2119451. View

Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E . Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med. 2022; 28(9):1785-1790. PMC: 9499863. DOI: 10.1038/s41591-022-01911-2. View

. COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(21):792-793. PMC: 8158893. DOI: 10.15585/mmwr.mm7021e3. View

Ter Meulen J, van den Brink E, Poon L, Marissen W, Leung C, Cox F . Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 2006; 3(7):e237. PMC: 1483912. DOI: 10.1371/journal.pmed.0030237. View

Beaudoin-Bussieres G, Laumaea A, Anand S, Prevost J, Gasser R, Goyette G . Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals. mBio. 2020; 11(5). PMC: 7569150. DOI: 10.1128/mBio.02590-20. View

Yu J, Collier A, Rowe M, Mardas F, Ventura J, Wan H . Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. N Engl J Med. 2022; 386(16):1579-1580. PMC: 9006770. DOI: 10.1056/NEJMc2201849. View

Hagglof T, Cipolla M, Loewe M, Chen S, Mesin L, Hartweger H . Continuous germinal center invasion contributes to the diversity of the immune response. Cell. 2022; 186(1):147-161.e15. PMC: 9825658. DOI: 10.1016/j.cell.2022.11.032. View

Ullah I, Prevost J, Ladinsky M, Stone H, Lu M, Anand S . Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. Immunity. 2021; 54(9):2143-2158.e15. PMC: 8372518. DOI: 10.1016/j.immuni.2021.08.015. View

Qu P, Faraone J, Evans J, Zheng Y, Carlin C, Anghelina M . Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants. Cell Rep. 2023; 42(5):112443. PMC: 10279473. DOI: 10.1016/j.celrep.2023.112443. View

10.

Goel R, Painter M, Lundgreen K, Apostolidis S, Baxter A, Giles J . Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. Cell. 2022; 185(11):1875-1887.e8. PMC: 8989683. DOI: 10.1016/j.cell.2022.04.009. View

11.

Zou J, Kurhade C, Patel S, Kitchin N, Tompkins K, Cutler M . Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine. N Engl J Med. 2023; 388(9):854-857. PMC: 9891359. DOI: 10.1056/NEJMc2214916. View

12.

Davis-Gardner M, Lai L, Wali B, Samaha H, Solis D, Lee M . Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster. N Engl J Med. 2022; 388(2):183-185. PMC: 9812288. DOI: 10.1056/NEJMc2214293. View

13.

Skowronski D, De Serres G . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2021; 384(16):1576-1577. DOI: 10.1056/NEJMc2036242. View

14.

Tauzin A, Gong S, Chatterjee D, Ding S, Painter M, Goel R . A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses. Cell Rep. 2022; 41(4):111554. PMC: 9533674. DOI: 10.1016/j.celrep.2022.111554. View

15.

Tauzin A, Nicolas A, Ding S, Benlarbi M, Medjahed H, Chatterjee D . Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine. Cell Rep. 2023; 42(1):111998. PMC: 9826988. DOI: 10.1016/j.celrep.2023.111998. View

16.

Tauzin A, Gendron-Lepage G, Nayrac M, Anand S, Bourassa C, Medjahed H . Evolution of Anti-RBD IgG Avidity following SARS-CoV-2 Infection. Viruses. 2022; 14(3). PMC: 8949389. DOI: 10.3390/v14030532. View

17.

Viana R, Moyo S, Amoako D, Tegally H, Scheepers C, Althaus C . Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022; 603(7902):679-686. PMC: 8942855. DOI: 10.1038/s41586-022-04411-y. View

18.

Groenheit R, Bacchus P, Galanis I, Sonden K, Bujila I, Efimova T . High Prevalence of SARS-CoV-2 Omicron Infection Despite High Seroprevalence, Sweden, 2022. Emerg Infect Dis. 2023; 29(6):1240-1243. PMC: 10202879. DOI: 10.3201/eid2906.221862. View

19.

Gili R, Burioni R . SARS-CoV-2 before and after Omicron: two different viruses and two different diseases?. J Transl Med. 2023; 21(1):251. PMC: 10088248. DOI: 10.1186/s12967-023-04095-6. View

20.

Beaudoin-Bussieres G, Tauzin A, Dionne K, Gendron-Lepage G, Medjahed H, Perreault J . A Recent SARS-CoV-2 Infection Enhances Antibody-Dependent Cellular Cytotoxicity against Several Omicron Subvariants following a Fourth mRNA Vaccine Dose. Viruses. 2023; 15(6). PMC: 10302413. DOI: 10.3390/v15061274. View